Status:
UNKNOWN
Evaluation of the Ambulatory Medical Assistance Nurse Program in Chronic Lymphocytic Leukemia
Lead Sponsor:
University Hospital, Toulouse
Conditions:
Chronic Lymphoid Leukemia
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The emergence of targeted therapy (ibrutinib, venetoclax, acalabrutinib) has revolutionized the management practices of chronic lymphoid leukemia due to their effectiveness. However, targeted therapy ...
Detailed Description
This research is a prospective randomized multicenter comparative study in 2 parallel groups (1: 1) : patients benefiting from the ambulatory medical assistance nurse program in addition to convention...
Eligibility Criteria
Inclusion
- Men and women over the age of 18
- Patients with chronic lymphoid leukemia and starting treatment with targeted therapy: ibrutinib, venetoclax or acalabrutinib, alone or in combination with obinutuzumab or rituximab in 1L or R/R according to the indications of the Marketing Authorization.
- Be able to understand the objective and the constraints related to the research
- Patient having signed the consent form
- Patient with Social Security affiliation or equivalent
- Person able to speak on the phone
Exclusion
- Patient who has already benefited from ambulatory medical assistance nurse program with a previous treatment
- Pregnant women
- Patients under judicial protection
Key Trial Info
Start Date :
April 13 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2025
Estimated Enrollment :
450 Patients enrolled
Trial Details
Trial ID
NCT05350826
Start Date
April 13 2023
End Date
July 1 2025
Last Update
September 21 2023
Active Locations (16)
Enter a location and click search to find clinical trials sorted by distance.
1
CH Sud Réunion
Saint-Pierre, ILE de LA Reunion, France
2
CHU d'Angers
Angers, France
3
CHU DE BREST Hôpital A.Morvan
Brest, France
4
Hôpital Estaing
Clermont-Ferrand, France